Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals The State...

Topics
Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals The State Street SPDR S&P Biotech ETF and State Street SPDR S&P Pharmaceuticals ETF carry identical 0.35% expense ratios. The State Street SPDR S&P Pharmaceuticals ETF has historically exhibited significantly lower price volatility and a smaller maximum drawdown than its biotech counterpart.
Related QATS news
- VFLO And CGDV: The Perfect Pairing For AI Growth VictoryShares Free Cash Flow ETF (VFLO) and Capita...
- BKLC: Zero Fees, Weak Risk-Reward BNY Mellon U.S. Large Cap Core Equity ETF (BKLC) offers zero-fee ...
- CGDV: Why Dividend Quality Matters More Than Quantity Capital Group Dividend Value ETF (CGDV) earns...
- VTG: A Low Cost But Smaller ETF, Facing Anti-Duration Macro Developments Vanguard Total Treasury ET...